Hirsutism Clinical Trial
Official title:
A 24 Week Randomised Double Blind Placebo Controlled Study to Evaluate the Atrophogenic Potential of Eflornithine in the Treatment of Women With Excessive Facial Hair
Verified date | October 2019 |
Source | Allergan |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate whether regular use of eflornithine 11.5% cream in treating women with facial hair will induce skin damage (atrophy) on the face and/or forearms
Status | Completed |
Enrollment | 78 |
Est. completion date | October 31, 2005 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Female subjects with clinical diagnosis of facial hirsutism/excessive facial hair - Women of childbearing potential must agree to use an effective form of birth control for the duration of the study - Skin type I-IV - Customary frequency of removal of facial hair two or more times per week Exclusion Criteria: - Pregnant or lactating women - Severe inflammatory acne or presence of significant scarring on the face - History of skin malignancy - Connective tissue disorders |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Allergan |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in facial skin thickness measured by ultrasound at 24 weeks | |||
Secondary | Skin biopsies | |||
Secondary | Histology and histochemistry in the dermis | |||
Secondary | Physician Global Assessment | |||
Secondary | Subject Self-Assessment Questionnaire |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02103608 -
Clinical Evaluation of Silk'n Glide for Face
|
N/A | |
Not yet recruiting |
NCT00495443 -
Enhanced Safety Aesthetic Laser System
|
N/A | |
Not yet recruiting |
NCT06003062 -
Suppression of Upper Lip Hair Growth Using Novel Hemp Extract
|
||
Active, not recruiting |
NCT00145288 -
Prospective Study of Patients With Hirsutism
|
Phase 2/Phase 3 | |
Enrolling by invitation |
NCT01461694 -
Facial Hair Reduction Using Intense Pulsed Light (IPL) & Alexandrite Laser
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT00441948 -
Enhanced Safety Laser Hair Removal System
|
N/A | |
Completed |
NCT03673995 -
Myoinositol Plus L-tyrosine, Selenium and Chromium in PCOS
|
N/A | |
Recruiting |
NCT04979377 -
Prevalence of Hyperandrogenism in Type 1 Diabetes
|
||
Completed |
NCT02494297 -
DUS on the Prescribing Indications for CPA/EE in 5 European Countries
|
||
Completed |
NCT00960310 -
Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions
|
Phase 1 | |
Completed |
NCT02793557 -
Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth
|
Phase 1/Phase 2 | |
Completed |
NCT01817894 -
Treatment With Topical Eflornithin After Laser Treatment in Women With Facial Hirsutism
|
Phase 4 | |
Completed |
NCT01555190 -
Combination Therapy With Myo-inositol and Folic Acid Versus Myo-inositol Alone
|
N/A | |
Completed |
NCT00143052 -
Bone Status and Insulin Resistance in Hirsutism
|
N/A | |
Recruiting |
NCT01338519 -
Database Study on Patients With PCOS
|
N/A | |
Recruiting |
NCT04292587 -
Prevalence of Hirsutism in Turkey: Data of The Dermatoendocrinology Study Group
|
||
Completed |
NCT00959335 -
Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions
|
Phase 1 | |
Not yet recruiting |
NCT00371930 -
Photodynamic Therapy for Permanent Hair Removal
|
Phase 1/Phase 2 |